The AHA today urged the Medicare Payment Advisory Commission to withdraw its draft recommendation to reduce Part B drug payment rates to hospitals participating in the 340B Drug Pricing Program. “This recommendation is outside of the scope of MedPAC’s mission, lacks a clear purpose and penalizes certain hospitals for their ability to obtain discounts on the items and services they purchase,” wrote Ashley Thompson, AHA senior vice president for public policy analysis and development. “The AHA strongly urges MedPAC to withdraw this draft recommendation and, instead, to undertake an analysis of the trend of rapidly increasing drug prices, which presents the Medicare program and its beneficiaries with remarkable challenges.” MedPAC expects to vote on payment recommendations for fiscal year 2017 later this week.

Related News Articles

Headline
The Medicare Hospital Insurance Trust Fund will have sufficient funds to pay full benefits until 2026, according to the latest annual report from the Medicare…
Headline
The Centers for Medicare…
Headline
Critical Access Hospitals, certain clinics, and other eligible outpatient facilities that provide primary care or substance use disorder treatment to high-need…
Headline
The Health Resources and Services Administration will host a webinar for applying for grants to coordinate maternal and obstetrics care in rural regions.
Headline
"Medicare for All" sounds like a good idea ... but we have a better way to meet today’s challenges, create a healthier tomorrow – and advance health in America.
Headline
Beginning June 11, hospitals, physicians and other eligible providers may submit notices of intent to apply to participate in the Jan. 1, 2020 start date for…